Publications by authors named "Emilio F Giunta"

Claim this Profile
L
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer.
Nicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, Francesco Orlando, Yari Ciani, Emilio Francesco Giunta

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Thomas Powles, Ariel G Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama, Emilio Francesco Giunta

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.
Irene Marini, Emilio Francesco Giunta, Silvia Nicolini, Ilaria Grassi, Flavia Foca

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients.
Alberto Farolfi, Chiara Casadei, Nicola Gentili, Sara Testoni, Francesca Rusconi, Emilio Francesco Giunta

Oncologist· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare epithelial gastric cancers: a review of the current treatment knowledge.
Angelica Petrillo, Margaret Ottaviano, Luca Pompella, Emilio Francesco Giunta, Pasquale Pisapia

Ther Adv Med Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of [Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.
Emilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, Amelia Altavilla, Virginia Rossetti

Eur J Nucl Med Mol Imaging· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group.
Emilio Francesco Giunta, Giandomenico Roviello, Vincenza Conteduca, Elena Verzoni, Giuseppe Procopio

Crit Rev Oncol Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari

Expert Rev Anticancer Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
Lorenzo Gasperoni, Emilio Francesco Giunta, Daniela Montanari, Carla Masini, Ugo De Giorgi

Expert Opin Drug Metab Toxicol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Emilio Francesco Giunta, Andrea Messori

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, Sara Elena Rebuzzi, Giuseppe Luigi Banna

Eur Urol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers.
Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, Federica Matteucci, Giovanni Paganelli

Cancer Treat Rev· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam

JAMA Netw Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
Chiara Casadei, Emanuela Scarpi, Vincenza Conteduca, Giorgia Gurioli, Maria Concetta Cursano, Emilio Francesco Giunta

Eur Urol Open Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-based liquid biopsy in advanced prostate cancer.
Emilio Francesco Giunta, Umberto Malapelle, Antonio Russo, Ugo De Giorgi

Crit Rev Oncol Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?
Emilio Francesco Giunta, Lorenzo Gasperoni, Ugo De Giorgi

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study.
Lucia Fratino, Jerry Polesel, Emilio Francesco Giunta, Marco Maruzzo, Sebastiano Buti

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transversal Perspectives of Integrative Oncology Care in Gastric and Lobular Breast Cancer.
Emilio Francesco Giunta, Gianluca Arrichiello, Annalisa Pappalardo, Piera Federico, Angelica Petrillo

Cancer Treat Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Matelda Medri, Francesco Savoia, Flavia Foca, Anna Miserocchi, Pietro Quaglino, Emilio F Giunta

Ital J Dermatol Venerol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.
Maria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, Chiara Casadei, Alessandra Virga

Int J Mol Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Reviews in gastrointestinal cancers.
Kanjoormana Aryan Manu, Fabrizio Bronte, Emilio Francesco Giunta

Front Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Giuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, Pasquale Rescigno, Axel Merseburger, Emilio F Giunta

Minerva Urol Nephrol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network.
Emilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, Ugo De Giorgi, Marco Maruzzo

Support Care Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact.
Piera Federico, Emilio Francesco Giunta, Andrea Tufo, Francesco Tovoli, Angelica Petrillo

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease.
Anju Jose, Maria Grazia Bavetta, Erika Martinelli, Fabrizio Bronte, Emilio Francesco Giunta

J Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis